Epidemiological profile, trend, seasonality, and factors 1 associated with Yellow fever disease and barriers to 2 vaccination: a retrospective observational study of multi-3 season national surveillance data in Nigeria, 2017 - 2021. 4 Stephen Eghelakpo Akar^{1,2,3}, William Nwachukwu³, Sunbo Oludare Adewuyi¹, Anthony 5 Agbakizua Ahumibe^{1,2}, Iniobong Akanimo³, Oveladun Okunromade³, Chinwe Ochu³, Olajumoke 6 Babatunde³, Ifedavo Adetifa³, Chikwe Ihekweazu⁴, Mami Hitachi², Kentaro Kato², Yuki 7 Takamatsu⁵, Kenji Hirayama⁶, Satoshi Kaneko^{2*} 8 ¹Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan 9 ²Department of Eco-epidemiology, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan 10 11 ³Nigeria Centre for Disease Control and Prevention, Abuja, Nigeria ⁴WHO Hub for Pandemic and Epidemic Intelligence, Berlin, Germany 12 13 ⁵Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan 14 ⁶School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan *Corresponding author 15 **Email:** skaneko@nagasaki-u.ac.jp (SK) 16 17

- 18
- 19
- 20

It is made available under a CC-BY 4.0 International license .

21 Abstract

22 Since its resurgence in 2017, Yellow fever (YF) outbreaks have continued to occur in Nigeria despite routine immunization and implementation of several reactive mass vaccination campaigns, 23 resulting in substantial morbidity and mortality. Nigeria is considered a high-priority country for 24 implementing the WHO EYE strategy, which is targeted at eliminating YF outbreaks by 2026. 25 This retrospective observational study was conducted to describe the epidemiological profile of 26 reported cases, trends, and seasonality of YF incidence; identify factors associated with Yellow 27 fever disease (YFD) and barriers to YF vaccination in Nigeria. Univariate, bivariate and 28 multivariate binary logistic regression analysis was done. Of 13014 suspected YF cases, 7640 29 30 (58.7%) had laboratory confirmation for Yellow fever virus (YFV). Predictors of YFD were male sex (aOR 2.36, 95% CI: 1.45-3.91) compared to female; age group being 15-29 years (aOR 4.13, 31 95% CI: 1.59-13.00) compared to under-five; residing in the Derived Savannah (aOR 30.10, 95% 32 33 CI: 11.50-104.00). Lowland/Mangrove/Freshwater rainforest (aOR 8.84, 95% CI: 3.24-31.10). Guinea Savannah/Jos Plateau (aOR 6.13, 95% CI: 1.90-23.50) compared to the Sahel/Sudan 34 35 savannah; working in outdoor settings compared to indoor (aOR 1.76, 95% CI: 0.96-3.22); and vomiting (aOR 2.62, 95% CI: 1.39-4.83). The rainy season was protective against YFD (aOR 0.32, 36 95% CI: 0.19-0.52) compared to the dry season. Because being unvaccinated emerged as 37 38 protective factor (aOR:0.51, 95% CI: 0.25-1.00) compared to those with unknown vaccination status, the data was further disaggregated by vaccination status. Predictors with higher odds ratios 39 were found among unvaccinated. Predictors of YFD among the vaccinated were the first quarter 40 41 compared to the second quarter of the year (aOR 4.04, 95% CI: 1.48-12.95) and residing in the southern region compared to the north (aOR 14.03, 95% CI: 4.09-88.27). Barriers to YF 42 vaccination were the rainy season compared to the dry season (aOR 1.29, 95% CI: 1.05-1.57), 43

It is made available under a CC-BY 4.0 International license .

being 15 years or older (15-29: aOR 2.06, 95% CI: 1.51-2.83; 30-44: aOR 2.11, 95% CI: 1.45-44 3.07; 45-59: aOR 2.72, 95% CI: 1.63-4.58; 60+: aOR 6.55, 95% CI: 2.76-17.50), residing in the 45 northern region (aOR 3.71, 95% CI: 3.01-4.58) compared to the south, and occupation being 46 butcher/hunter/farmer (aOR 2.30, 95% CI: 1.52-3.50) compared to home-based/office workers. 47 Being a student was protective against being unvaccinated (aOR 0.62, 95% CI: 0.47-0.83). Several 48 49 factors were associated with YFD, which were aggravated by lack of vaccination. Although barriers to vaccination were elucidated, inadequate vaccination coverage alone may not account 50 for the recurrent outbreaks of YF in Nigeria. These findings are critical for planning public health 51 interventions and to guide further research that would enable Nigeria end YF epidemics. 52

53 Introduction

Yellow fever (YF), an arthropod-borne, re-emerging viral hemorrhagic illness, caused by the 54 Yellow fever virus (YFV), has remained a significant public health concern in Africa and the 55 Americas, accounting for about 29,000 to 60,000 deaths annually [1–8]. An effective and safe 56 57 vaccine against YFV, the live attenuated YF 17D vaccine, has been available for over seventy years and integrated into routine immunization (RI) program in endemic countries. The vaccine 58 has been shown to confer 95% protection in vaccinated populations within 30 days of vaccine 59 uptake and offers life-long immunity [5,6,9–13]. Infected persons present with a broad spectrum of 60 61 clinical disease, ranging from asymptomatic infections and mild febrile illness to severe disease and death. It is estimated that 15-25% of infected symptomatic persons progress to severe disease 62 with a case fatality rate of 20-60% [6,14]. 63

Despite the existence of RI for YF and the implementation of several mass preventative and reactive vaccination campaigns, YF outbreaks have continued to occur in Nigeria since its resurgence in 2017. Previous studies in Nigeria have focused on the descriptive epidemiology of

It is made available under a CC-BY 4.0 International license .

outbreak cases [6,11] and vaccination program implementation [5,15]. Tobin *et al.* (2021) assessed
the knowledge and attitudes towards YF in a cross-sectional study conducted in a small community
in one of the hotspots states in southern Nigeria [16]. There is paucity of studies on the factors
associated with YFD and YF vaccination in Nigeria. The trend and seasonality of YF in Nigeria
has not also been adequately described.

The Eliminate Yellow fever Epidemics (EYE) strategy of the World Health Organization is 72 targeted at eliminating YF outbreaks in endemic countries by the year 2026, and Nigeria is 73 considered a high priority country for its implementation [17]. The EYE strategy is aimed at 74 protecting at-risk population, preventing international spread of YF, and containing local outbreaks 75 of YF promptly [17]. The objective of this study is to describe the epidemiological profile of 76 77 reported YF cases, trends, and seasonality of YF incidence; as well as identify factors associated with YFD and barriers to YF vaccination in Nigeria. This has become imperative as public health 78 79 authorities aim to develop strategic public health interventions to enable the country to meet the 80 2026 target of the WHO EYE strategy.

81 Methods

82 Data Source Description

We retrospectively analyzed YF surveillance data obtained from the Surveillance, Outbreak, Response, Management, and Analysis System (SORMAS) platform managed by the Nigeria Centre for Disease Control (NCDC) to which State ministries and Local Government departments of health reported. SORMAS in Nigeria, part of the integrated disease surveillance and response system (IDSR), has been previously described [5,11]. In brief, once a patient meets the standard case definition for a suspected case of YF, the attending physician notifies the Local Government Area (LGA) Disease Surveillance and Notification Officer (DSNO); the LGA DSNO then notifies

the State Epidemiologist and the State DSNO, who verifies the case and then inform the focal 90 person at the NCDC. The NCDC, in conjunction with the State and the LGA officers, constitutes 91 an outbreak investigation team to investigate the case using a case investigation form (CIF). The 92 cases are line-listed, and blood samples are collected for laboratory confirmation in line with the 93 National Guidelines for YF Preparedness and Response [5,18]. Serological testing involved the 94 95 detection of YF-specific antibodies in the serum samples of suspected cases using Enzyme-linked Immunosorbent Assay (ELISA; U.S. CDC MAC protocol; done in-country) and plaque reduction 96 neutralization test (PRNT; done at the Regional Reference Laboratory, Dakar, Senegal). ELISA 97 positive results were recorded as "presumptive positive" while negative results were recorded as 98 "negative cases". Both ELISA positive samples and "inconclusive samples" were sent to the 99 Regional Reference Laboratory for confirmation by PRNT. Molecular testing by real-time 100 polymerase chain reaction (RT-PCR) was done in-country for samples collected from suspected 101 cases within ten days of onset of symptoms to detect YF viral genome in blood. PCR negative 102 103 samples were further tested by serology to rule out false negative results while positive samples are reported as confirmed YF cases [18]. Information on the CIF is logged into the SORMAS 104 105 platform using the epidemiological number issued by the State Epidemiologist as a unique 106 identifier. The data abstracted from the SORMAS platform include epidemiological number, socio-demographic information (age, sex, education, occupation), vaccination status, clinical 107 108 information (date of onset, date of admission, symptoms), location (state), trave history, and 109 laboratory test status (negative, positive, unconfirmed) from July 2017 to December 2021.

110 Case definition

111 The case definitions applied for YF surveillance in Nigeria are as follows: A suspected case of YF 112 was defined as "any person with acute onset of fever or history of fever and/or general body

weakness, vomiting, bleeding from any part of the body, and jaundice appearing within 14 days 113 of onset of the first symptom" [18]. A presumptive case was defined as a "suspected case in whom 114 115 was found the presence of YF IgM antibody in the absence of YF vaccination within the last 30 days before onset of illness or positive post-mortem liver histopathology or epidemiological link 116 to a confirmed case or an outbreak". A confirmed case was defined as "presumptive case with one 117 118 of the following: detection of YF IgM; detection of four-fold rise in IgM or IgG antibody titers between acute and convalescent serum samples or both; detection of YF-specific neutralizing 119 antibodies and absence of YF immunization within 30 days before onset of illness or one of the 120 following: detection of YF viral genome in blood, liver or other organs by immunoassay, isolation 121 of YF virus and absence of YF immunization within 14 days before onset of illness [18]. However, 122 123 for this study, a positive case was defined as a suspected case that was confirmed positive for YFV 124 by either serology or RT-PCR. A negative case is a suspected case that was confirmed negative by both serology and RT-PCR. An unconfirmed case is a suspected case for which laboratory test 125 126 result was missing in the line list.

127 Additional data sources for the analysis

Administratively, Nigeria has 774 LGAs, which are clustered into 36 states and the Federal Capital 128 Territory and zoned into six geo-political zones (North-Central, North-East, North-West, South-129 East, South-West, and South-South). The geo-political zones were created based on political and 130 socio-cultural considerations from the northern and southern regions. There are two climatic 131 seasons in Nigeria (dry season and rainy season). The rainy season begins in April and ends in 132 October while the dry season commences from November and terminates at about the end of 133 March [19]. Forests spanned over nine ecological zones [20] (S1 Fig). The northern part of the 134 country is dotted with Savannah-type vegetation whereas the southern region is characterized by 135

It is made available under a CC-BY 4.0 International license .

weather conditions that promote luxuriant rainforest and proliferation of insect populations. It is 136 estimated that forest reserves occupy 10% of the total land mass, with 78.7% in the Savannah zone, 137 7.7% in the derived Savannah zone, and 13.6% in the rain forest zone [19,21]. The ecological 138 zones have been described as running from the northern to the southern parts in a contiguous 139 fashion, in which natural ranges extending from the mangrove swamps and tropical forests in the 140 141 coastal flanks become shrubs and Savannah woodlands in the low Plateau, which extends into the semi-arid plains of the northern region in central Nigeria and the eastern highlands. This complex 142 mesh of forest pattern had resulted in a variety of vegetation in the landscape, including Sahel, 143 Guinea, and derived Savannah as well as lowland rain forest, freshwater and mangrove forests, 144 coastal marshes, and estuaries. The ecological zones are repositories of a wide variety of plants 145 and animal species, including 20,000 insect and 247 mammalian species [19]. The variables geo-146 political zone, geographical region, and ecological zone were generated based on the states in 147 which cases were reported. 148

Definition of variables

Time-oriented variables such as annual quarter, epidemic period (pre-pandemic, pandemic) and 150 climatic season (dry season, rainy season) were generated by grouping cases by date of onset of 151 illness. Epidemic period was defined as whether a case developed symptoms before (pre-152 pandemic) or during (pandemic) the period of the COVID-19 pandemic (January 2020 and 153 beyond) while climatic season was defined as whether the case occurred during the months of the 154 dry season or the rainy season. Socio-demographic factors presumed to be associated with outcome 155 156 variables were identified from previous studies [2,4,22]. Age in years and sex were analyzed as reported by cases and relatives. Age was used to create two sets of age group variables: For the 157 analysis of factors associated with outcome variables (YFD and being unvaccinated) without 158

disaggregation, age was categorized into seven levels (0-4, 5-9, 10-14, 15-29, 30-44, 45-59, and 159 60+ years); however, when YFD was disaggregated by vaccination status, age was categorized 160 into two levels (<15 and >=15 years) to accommodate small sample sizes. Geo-political zone, 161 geographical region, and ecological zone were generated using the state in which cases were 162 detected. Educational status was created from the educational level reported by cases – primary, 163 164 secondary, tertiary, Islamic education, no education. These were collapsed into two levels: all those who had any formal education were defined as "educated" and those with no education were 165 defined as "no education" alongside those who did not report their educational status, considering 166 167 the current illiteracy level of nearly 40.0% in Nigeria. Occupational group was generated from the occupation reported by cases, which were loosely defined. Those working in office settings, 168 housewives, and kids below school age were grouped as "home-based/office workers"; those who 169 170 reported business, trading, plumbing, electrician etc. were grouped as "artisans/traders". In Nigeria the term "business" loosely includes people involved in any form of buying and selling of goods 171 and services. Cases who were of school age (6-17 years) but were not reported as students were 172 grouped as "students" alongside those who reported being students based on the premise that basic 173 education is mandatory by law in Nigeria. Those involved in animal sales, butchers, hunters, and 174 farmers were grouped as "butchers/farmers/hunters"; and those working in healthcare settings 175 were defined as health workers. Cases who reported no occupation were defined as unemployed 176 177 in view of the high unemployment rate in Nigeria.

178 Statistical analysis

De-identified and anonymized national line-list of YF outbreak cases from 1st July 2017 to 31st December 2021 was abstracted from the SORMAS platform in compliance with NCDC data sharing protocol. We received the dataset in Microsoft Excel format from the data management on

It is made available under a CC-BY 4.0 International license .

182 5th February 2022 with personal identifiers of the cases removed. Categorical variables were summarized using frequencies and percentages while numerical variables were summarized using 183 median and inter-quartile range. Our main outcome variables were: (1) YFD, defined as a 184 suspected case of YF confirmed for YFV by either serology or RT-PCR (a categorical variable 185 with two levels: No = No YFD, Yes = YFD) and (2) unvaccinated, defined as a suspected with no 186 previous YF vaccination before the onset of symptoms (a categorical variable with two levels: 187 No/Yes). Comparison of percentages between outcome and explanatory variables was done using 188 Pearson's Chi square statistic and Fisher's exact test for categorical variables and Kruskal-Wallis 189 190 rank sum test for numerical variables with p-value <0.05 considered to be statistically significant. We used date of onset of illness to plot epidemic curves with trend lines (histogram with line plots) 191 and time series seasonality plots (line plot in which cases were aggregated by months over the 192 193 entire study period) to show trends of cases over time. A population-adjusted age-sex pyramid of cases was also plotted using the ages of cases and country age-sex population structure. 194

At bivariate analysis, odds ratio (OR) was used as a measure of association between seasonal, 195 geographical, socio-demographic, and clinical characteristics and respective outcome variables 196 (YFD: No = 0, Yes = 1; unvaccinated: No = 0; Yes = 1) and the 95% confidence intervals with p-197 values (<0.05) were estimated. Subsequently, multivariate logistic regression analysis was done 198 using stepwise selection process, which was based on Akaike Information Criterion (AIC) [23] -199 implemented in R using the *stepAIC* function in the MASS package [24] with backward selection. 200 201 Here, explanatory variables with level of significance p<0.15 at bivariate analysis were included in the multivariate logistic regression model to determine adjusted odds ratios, 95% confidence 202 interval, and p-values of predictors of the respective outcomes. We used variance inflation factor 203 204 to assess multicollinearity of the variables in the final model and variables that exhibited

205 collinearity values ≥ 5.0 were excluded from the final model. For variables that exhibited collinearity, the one with a higher variance inflation factor was dropped from the final model. For 206 both outcome variables, bivariate and multivariate analysis was first done with the whole dataset 207 and then disaggregated by vaccination status (YFD) and laboratory test result (being 208 unvaccinated). We conducted our analysis with RStudio version 4.4.2 and R version 4.4.2 209 210 (http://posit.co/download/rstudio-desktop/). The main R packages used in our analysis were the tidyverse package (data wrangling) [25], tableone package (descriptive table) [26], gtsummary and 211 finalfit packages (bivariate and multivariate analysis)[27], and TSstudio package (seasonality 212 analysis)[28]. 213

214 Ethical consideration

Approval for this study was sought by submission of the study proposal (see Other supporting 215 material) to the Research Ethics Committee of the Nigeria Centre for Disease Control and 216 Prevention, which was reviewed and approved. The Research Ethics Committee then requested 217 the authors to complete, sign, and submit a data sharing agreement form to access the dataset (see 218 Other supporting material). The data has been previously collected, stored, and analyzed as part of 219 220 outbreak response activity by the NCDC during which a case investigation form was administered by trained clinical staff to obtain relevant information from suspected cases of YF to which they 221 consented in writing following detailed explanation about the use of their information by 222 223 appending their signature and witnessed by an attending nurse and a family relative. In the case of minors, informed consent was given by either a parent or guardian. The data was confidentially 224 stored in passworded computer systems by NCDC data management team and was shared in de-225 identified and anonymized Microsoft Excel format for this study. This necessitated a waiver of the 226 need for informed consent for this study by the Research Ethics Committee. 227

It is made available under a CC-BY 4.0 International license .

228 **Results**

229 Trend and seasonality of case incidence

- 230 Case reporting was higher during the 2019 epidemic season (34.0%) while YFV positive case was
- higher during the 2020 epidemic season (44.0%). While suspected case reporting was higher
- during the third and fourth quarter of the year, YFV positivity was more in the fourth quarter of
- the year (Table 1).

Table 1. Seasonal, geographical, and socio-demographic characteristics of YF cases in Nigeria, 2017 and 2021 compared by laboratory test status.

Variable	Category	Overall	Unconfirmed	YFV Negative	YFV Positive	p-value
No.		13014	5374	7104	536	
		n (%)	n (%)	n (%)	n (%)	
Epidemic season	2017	1229 (9.4)	428 (8.0)	778 (11.0)	23 (4.3)	< 0.001
	2018	1922 (14.8)	1154 (21.5)	760 (10.7)	8 (1.5)	
	2019	4430 (34.0)	1828 (34.0)	2392 (33.7)	210 (39.2)	
	2020	3552 (27.3)	1228 (22.9)	2088 (29.4)	236 (44.0)	
	2021	1881 (14.5)	736 (13.7)	1086 (15.3)	59 (11.0)	
Annual quarter	First quarter	3001 (23.1)	710 (13.2)	2198 (30.9)	93 (17.4)	< 0.001
	Second quarter	2425 (18.6)	813 (15.1)	1593 (22.4)	19 (3.5)	
	Third quarter	3774 (29.0)	1806 (33.6)	1834 (25.8)	134 (25.0)	
	Fourth quarter	3814 (29.3)	2045 (38.1)	1479 (20.8)	290 (54.1)	
Epidemic period	Pandemic	5433 (41.7)	1964 (36.5)	3174 (44.7)	295 (55.0)	<0.001
	Pre-pandemic	7581 (58.3)	3410 (63.5)	3930 (55.3)	241 (45.0)	
Climatic season	Dry season	5423 (41.7)	1964 (36.5)	3152 (44.4)	307 (57.3)	< 0.001
	Rainy season	7591 (58.3)	3410 (63.5)	3952 (55.6)	229 (42.7)	
Geo-political zone	North-central	1892 (14.5)	703 (13.1)	1110 (15.6)	79 (14.7)	< 0.001
	North-east	1896 (14.6)	826 (15.4)	946 (13.3)	124 (23.1)	
	North-west	3727 (28.6)	1892 (35.2)	1793 (25.2)	42 (7.8)	
	South-east	2622 (20.1)	1142 (21.3)	1335 (18.8)	145 (27.1)	
	South-south	1689 (13.0)	585 (10.9)	997 (14.0)	107 (20.0)	
	South-west	1188 (9.1)	226 (4.2)	923 (13.0)	39 (7.3)	
Ecological zone	Derived savannah	3431 (26.4)	1398 (26.0)	1825 (25.7)	208 (38.8)	< 0.001
	Freshwater/mangrove/coastal forest	999 (7.7)	297 (5.5)	626 (8.8)	76 (14.2)	
	Guinea savannah	949 (7.3)	356 (6.6)	579 (8.2)	14 (2.6)	
	Jos plateau	1033 (7.9)	427 (7.9)	492 (6.9)	114 (21.3)	
	Lowland rainforest	1836 (14.1)	552 (10.3)	1222 (17.2)	62 (11.6)	
	Sahel savannah	1095 (8.4)	548 (10.2)	536 (7.5)	11 (2.1)	
	Sudan savannah	3671 (28.2)	1796 (33.4)	1824 (25.7)	51 (9.5)	
Sex	Female	5658 (43.5)	2253 (41.9)	3210 (45.2)	195 (36.4)	< 0.001
	Male	7356 (56.5)	3121 (58.1)	3894 (54.8)	341 (63.6)	
Age [median {IQR}] years		18.0 [7.0, 30.0]	18.0 [7.0, 30.0]	16.0 [7.0, 29.0]	20.0 [12.0, 30.0]	<0.001
Age group	0-4years	1875 (14.4)	744 (13.8)	1100 (15.5)	31 (5.8)	<0.001
	5-9years	2088 (16.0)	817 (15.2)	1202 (16.9)	69 (12.9)	
	10-14years	1483 (11.4)	588 (10.9)	841 (11.8)	54 (10.1)	
	15-29years	3936 (30.2)	1707 (31.8)	2005 (28.2)	224 (41.8)	
	30-44years	2024 (15.6)	897 (16.7)	1039 (14.6)	88 (16.4)	
	45-59years	737 (5.7)	302 (5.6)	397 (5.6)	38 (7.1)	
	60+years	376 (2.9)	143 (2.7)	224 (3.2)	9 (1.7)	
	Unknown	495 (3.8)	176 (3.3)	296 (4.2)	23 (4.3)	
Educational status	Educated	2015 (15.5)	875 (16.3)	1047 (14.7)	93 (17.4)	0.029
	No education	10999 (84.5)	4499 (83.7)	6057 (85.3)	443 (82.6)	

It is made available under a CC-BY 4.0 International license .

Variable	Category	Overall	Unconfirmed	YFV Negative	YFV Positive	p-value
Occupational setting	Indoor	3413 (26.2)	1575 (29.3)	1688 (23.8)	150 (28.0)	< 0.001
	Outdoor	828 (6.4)	452 (8.4)	330 (4.6)	46 (8.6)	
	Unknown	8773 (67.4)	3347 (62.3)	5086 (71.6)	340 (63.4)	
Occupation status	Artisan/trader	371 (2.9)	183 (3.4)	176 (2.5)	12 (2.2)	<0.001
	Home-based/office work	5376 (41.3)	2095 (39.0)	3106 (43.7)	175 (32.6)	
	Healthcare worker	44 (0.3)	17 (0.3)	26 (0.4)	1 (0.2)	
	Hunter/butcher/animal trade/farmer	798 (6.1)	436 (8.1)	318 (4.5)	44 (8.2)	
	Student	1323 (10.2)	606 (11.3)	645 (9.1)	72 (13.4)	
	Unemployed	5102 (39.2)	2037 (37.9)	2833 (39.9)	232 (43.3)	
Traveled within last 2 weeks	No	12755 (98.0)	5228 (97.3)	7022 (98.8)	505 (94.2)	<0.001
	Yes	259 (2.0)	146 (2.7)	82 (1.2)	31 (5.8)	
Vaccination status	Unknown	9031 (69.4)	3492 (65.0)	5093 (71.7)	446 (83.2)	<0.001
	Unvaccinated	2248 (17.3)	1241 (23.1)	981 (13.8)	26 (4.9)	
	Vaccinated	1735 (13.3)	641 (11.9)	1030 (14.5)	64 (11.9)	

Numbers are N(%) unless otherwise noted.

IQR = interquartile range.

Table 1 Cont

Overall refers to all suspected YF cases reported throughout the study period.

Unconfirmed refers to suspected cases that were not confirmed by either serology or PCR.

Statistically significant p-values are in bold text.

237

The highest peak of case reporting and YFV case positivity were seen around Week 43 in the 2020
epidemic season (Fig 1A). The highest incidence of involvement of vaccinated cases was seen
during week 34-43 of the 2019 epidemic season (Fig 1B). The initiation of YF vaccination
(reactive and preventive) campaign between 2017 and 2018 apparently resulted in a flattening of
the 2018 epidemic peak (around week 35-40).

Fig 1. Time trends of incidence of YF cases in Nigeria, 2017-2021. Lines indicate weekly mean
incidence. In: (A) average weekly incidence were stratified by laboratory test result; (B) average
weekly incidence disaggregated by vaccination status. Light blue histogram background is the
epidemic curve of all suspected cases.

248

249 The North-west geo-political zone presented a somewhat characteristic trend of case incidence

250 pattern with several peaks seen over the entire period, usually during the dry season (highest peak

seen between week 34 and 43 of the 2019 epidemic season), which were much larger in magnitude

It is made available under a CC-BY 4.0 International license .

and longer in duration, except during the 2020 epidemic season (Fig 2A). This pattern was found
to be inherent in the Sahel Savannah ecological zone (Fig 2B).

254

Fig 2. Trends of incidence of reported YF cases in Nigeria, 2017-2021. Lines indicate weekly mean incidence. In: (A) cases were disaggregated by geo-political zone; and (B) cases were disaggregated by ecological zone. Light blue histogram background is the epidemic curve of all reported cases.

259

The 2020 epidemic season presented the most distinct trend pattern throughout the entire period in which the highest peak incidence seen in the South-east geo-political zone reflected the outbreak pattern of the Derived Savannah. Annually, YF case reporting increased progressively from about the middle of the rainy season between June and July with the peak incidence seen sometime between September and November (Figs 3A and B).

265

Fig 3. Seasonality plot of reported Yellow fever cases in Nigeria, 2017-2021. (A) all suspected cases, (B) YFV confirmed cases. Cases were aggregated by month in a line plot over the entire period.

269

Overall case reporting was higher during the pre-pandemic era (2016-2019; 58.3%) while YFV
positive case was more during the COVID-19 pandemic era (2020-2021; 55.0%; <0.001) (Table
1).

273

274

It is made available under a CC-BY 4.0 International license .

275 Socio-demographic and clinical characteristics

Between July 1, 2017 and December 31, 2021, Nigeria recorded a total of 13,014 suspected YF 276 cases, of which 7640 (58.7%) had laboratory confirmation by either serology or RT-PCR. Overall 277 YFV case positivity was 7.02% (536/7640). Median age was higher among YFV positive cases 278 279 (median= 20.0 years; IOR= 12.0 - 30.0 years) (Table 1). The most affected age group were those 15-29 years, who also accounted for about 30.0% (64,883,373) of the total population and about 280 32.0% (3936) of all suspected cases (Fig 4A). They were also the most unvaccinated group (Fig 281 4C) and had the largest proportion of persons with unknown vaccination status (Fig 4D). 282 283 Fig 4. Age-sex pyramid of Yellow fever cases in Nigeria, 2017-2021. From left to right: (A) all 284 reported cases, (B) vaccinated cases, (C) unvaccinated cases, and (D) cases of unknown 285 vaccination status. The percentage of cases were superimposed on country age-sex population 286

structure. Pink = female and blue = male. The light-shaded bars indicate country demographic agesex structure.

289

Cases were mostly males (all: 56.5%; positive: 63.6%; negative: 54.8%; unconfirmed: 58.1%; p<0.001). Case reporting was higher in the Sudan Savannah (28.2%) whereas YFV positive case was more in the Derived Savannah (38.8%, p<0.001) ecological zone. They were predominantly of uneducated (all: 84.5%; positive: 82.6%; negative: 85.3%; unconfirmed: 83.7%; p=0.029); mostly home-based or working in office setting (41.3%), but the unemployed had higher YFV case positivity (43.3%, p<0.001). They were largely of unknown vaccination status (all: 69.4%; positive: 83.2%; negative: 71.7%; unconfirmed: 65.0%; p<0.001) (Table 1).

It is made available under a CC-BY 4.0 International license .

297	Clinical symptoms commonly presented among reported cases were fever (63.9%), jaundice
298	(28.7%), headache (16.1%), fatigue (11.6%), dark urine (7.1%), and vomiting (6.1%). YFV
299	positive cases presented more with fever (70.9%) and had a higher admission rate (11.9%) (Fig 4).
300	

Fig 5. Clinical characteristics of reported Yellow fever cases in Nigeria, 2017-2021. (A) all
 reported cases, and (B) YFV confirmed cases. Yellow bar = symptom is present (Yes), purple bar
 = symptom not presented, and green bar = missing data.

304

Seasonal, geographical, socio-demographic, and clinical factors associated with YFD.

307 Factors associated with YFD are shown in Table 2. Independent predictors of YFD were male sex 308 compared to female (aOR: 2.36, 95% CI: 1.45–3.91; p<0.001); age group being 15-29 years compared to under-fives (aOR: 4.13, 95% CI: 1.59–13.00, p=0.007); residing within the Derived 309 Savannah, Lowland/Mangrove/Freshwater rainforest, and the Guinea Savannah/Jos Plateau 310 311 compared to the Sahel/Sudan Savannah (aOR: 30.10, 95% CI: 11.50–104.00; aOR: 8.84, 95% CI: 3.24–31.10; aOR: 6.13, 95% CI: 1.90–23.50 respectively, p<0.001). Working in outdoor setting 312 was associated with YFD but not statistically significant (aOR: 1.76, 95% CI: 0.96–3.22, p=0.067). 313 314 Clinical predictor of YFD was presenting with vomiting (aOR: 2.62, 95% CI: 1.39–4.83; p=0.002). The rainy season was protective against YFD (aOR: 0.32, 95% CI: 0.19–0.52, p<0.001). 315 316

317

It is made available under a CC-BY 4.0 International license .

319 Table 2. Seasonal, geographical, socio-demographic, and clinical factors associated with YFD

among reported cases in Nigeria, 2017-2021.

		Uni	variate	Multivariable			
-		N=	-7640				
Characteristic	Total	Crude OR	95% CI	p-value	Adjusted OR	95% CI	p-value
Epidemic season	7,640				,		
2017		1.00	Ref	< 0.001			
2018		0.36	0.15, 0.77				
2019		2.97	1.96, 4.72				
2020		3.82	2.53, 6.07				
2021		1.84	1.14, 3.06				
Annual quarter	7,640						
First quarter		3.55	2.21, 6.01	<0.001			
Second quarter		1.00	Ref				
Third quarter		6.13	3.87, 10.3				
Fourth quarter		16.4	10.6, 27.2				
Epidemic period	7,640						
Pre-pandemic		1.00	Ref	< 0.001			
Pandemic		1.52	1.27, 1.81				
Climatic season	7,640						
Dry season		1.00	Ref	<0.001	1.00	Ref	<0.001
Rainy season		0.59	0.50, 0.71		0.32	0.19, 0.52	
Geo-political zone	7,640						
North-west	Ĺ	1.00	Ref	<0.001			
North-central		3.04	2.09, 4.49				
North-east		5.60	3.94, 8.10				
South-east		4.64	3.30, 6.66				
South-south		4.58	3.21, 6.67				<u> </u>
South-west		1.80	1 16 2.81				<u> </u>
Ecological zone	7 640	1.00					
Sahel/Sudan Savannah	7,010	1.00	Ref	<0.001	1.00	Ref	<0.001
Derived Savannah		4 34	3 27 5 84	-0.001	30.10	11 50 104 00	-0.001
Lowland/Freshwater/Mangrove rainforest		2.84	2.10.3.88		8 84	3 24 31 10	
Guinea Savannah/Ios Plateau		4 55	3 35 6 25		6.13	1 90 23 50	
Sex	7 611	1.55	5.55, 0.25		0.15	1.90, 25.50	
Female	7,011	1.00	Ref	<0.001	1.00	Ref	<0.001
Male		1.00	1 19 1 71	-0.001	2 36	1 45 3 91	-0.001
Age group	7 321	1.42	1.19, 1.71		2.50	1.45, 5.91	
0_4 years	7,521	1.00	Ref	<0.001	1.00	Ref	0.007
5-9 years		2.04	1 34 3 18	-0.001	1.00	0.65.6.57	0.007
10-14 years		2.04	1.04, 0.10		1.94	0.60, 6.99	
15-29 years		3.96	2 75 5 92		4.13	1 59 13 0	
30 44 years		3.01	2.75, 5.72		2.36	0.76, 8.30	
45 50 years		3.01	2.00, 4.03		2.30	0.70, 8.39	
60+ years		1.43	0.63 2.02		1.33	0.15, 8.38	
Educational status	7.640	1.45	0.03, 2.92		1.55	0.15, 8.58	
Educational status Educated	7,040	Ref	1.00	0.100			+
No education		0.82	0.66.1.04	0.100			+
Occupational group	7.640	0.82	0.00, 1.04				
Homo/office worker	7,040	1.00	Pof	<0.001			
Unamplayed		1.00	1 10 1 79	~0.001			
Student		1.43	1.19, 1.70				┼────
		1.98	1.40, 2.03				
		2.40	1./1, 3.43				
Hoolthoore worker		1.21	0.05, 2.12				┼───
Compation softing	2 214	0.08	0.04, 3.24				+
Occupation setting	2,214	1.00	D.C.	<0.001	1.00	DC	
	-	1.00	Ket	<0.001	1.00	Ket	0.06/
	7.640	2.30	1./1, 3.11		1./6	0.96, 3.22	───
I raveled within last 2 weeks	/,640	1.00	D C	-0.001			───
No		1.00	Ket	<0.001			───
Yes	7.640	5.26	3.40, 7.94				───
Vaccination status	/,640						L

It is made available under a CC-BY 4.0 International license .

321

Table 2 Cont.

		Uni	variate		Multivariable				
		N=	=7640						
Characteristic	Total	Crude OR	95% CI	p-value	Adjusted OR	95% CI	p-value		
Unknown		1.00	Ref	<0.001	1.00	Ref	0.057		
Unvaccinated		0.30	0.20, 0.44		0.51	0.25, 1.00			
Vaccinated		0.71	0.54, 0.92		1.01	0.55, 1.82			
Anorexia	3,061		<u></u>			,			
No		1.00	Ref	0.14					
Yes		0.68	0.39, 1.10						
Dark urine	2,952		Í Í						
No		1.00	Ref	0.022					
Yes		0.55	0.32, 0.89						
Fatigue	3,112								
No		1.00	Ref	0.016					
Yes		1.45	1.07, 1.94						
Hemorrhagic symptoms	2,992		<u>í</u>						
No		1.00	Ref	<0.001					
Yes		5.18	1.83, 12.9						
Vomiting	3,095								
No	- É	1.00	Ref	<0.001	1.00	Ref	0.002		
Yes		2.51	1.76, 3.52		2.62	1.39, 4.83			
OR = Odds Ratio	·	•				,			

CI = Confidence Interval

Statistically significant p-values are in bold text.

322

Considering the higher YFV positivity rate among vaccinated cases compared to the unvaccinated 323 and the fact that being unvaccinated emerged as a protective factor in our final multivariate logistic 324 regression analysis, we further disaggregated the dataset by vaccination status and analyzed the 325 326 predictors of YFD by sub-group. The odds of YFD were higher among the unvaccinated and those with unknown vaccination status compared to those with previous YF vaccination (Table 3). 327 Factors associated with YFD among those with unknown vaccination status were the first, third 328 329 and last guarter of the year compared to the second guarter (OR: 4.27, 95% CI: 2.22-9.26; OR: 9.24, 95% CI: 4.95–19.80, and OR: 24.50, 95% CI: 13.38–51.60, p<0.001); the covid-19 330 pandemic period (OR: 1.84, 95% CI: 1.51–2.23; p<0.001); the rainy season (OR: 1.39, 95% CI: 331 1.12–1.71; p=0.003); male sex (OR: 1.45, 95% CI: 1.19–1.78; p<0.001); age being 5 years or older 332 compared to being four years and below (5-9 year: OR: 2.16, 95% CI: 1.33-3.62; 10-14 years: 333 OR: 2.60, 95% CI: 1.57–4.41; 15-29 years: OR: 4.37, 95% CI: 2.88-6.98; 30-44 years: OR: 2.96, 334 95% CI: 1.86–4.89; 45-59 years: OR: 3.56, 95% CI: 2.07–6.21; p<0.001); residing within the 335

It is made available under a CC-BY 4.0 International license .

- 336 Derived Savannah, the Lowland/Freshwater/Mangrove rainforest, and the Guinea Savannah/Jos
- 337 Plateau compared to the Sahel/Sudan Savannah (OR: 3.78, 95% CI: 2.80–5.16, OR: 2.01, 95%
- 338 CI: 1.45–2.83, OR: 4.35, 95% CI: 3.15–6.07 respectively; p<0.001); being unemployed, student,
- and butcher/hunter/farmer (OR: 1.26, 95% CI: 1.01–1.57; OR: 2.40, 95% CI: 1.69–3.35; and OR:
- 340 3.33, 95% CI: 2.15–5.03; p<0.001); working in outdoor settings (OR: 2.21, 95% CI: 1.55–3.17;
- p<0.001); having traveled within last two weeks preceding onset (OR: 5.53, 95% CI: 3.45–8.65),
- 342 presenting with fatigue, jaundice, and vomiting (OR: 1.97, 95% CI: 1.38–2.77, p<0.001; OR: 1.50,
- 343 95% CI: 1.12–2.02; p=0.007; and OR: 2.37, 95% CI: 1.55–3.56, p<0.001).

Table 3. Seasonal, geographical, socio-demographic, clinical factors associated with YFD among reported cases in Nigeria, 2017-2021 disaggregated by vaccination status.

	Vaccinated				Unvaccinated				Unknown status			
Characteristic	Total	cOR	95% CI	p-value	Total	cOR	95% CI	p-value	Total	cOR	95% CI	p-value
Annual quarter	1,094				1,007				5,539			
First quarter		3.51	1.61, 8.80	0.017		1.32	0.29, 6.73	< 0.001		4.27	2.22, 9.26	<0.001
Second quarter		1.00	Ref			1.00	Ref			1.00	Ref	
Third quarter		2.97	1.26, 7.79			2.28	0.60, 10.9			9.27	4.95, 19.8	
Fourth quarter		2.48	0.94, 6.95			13.2	4.16, 58.5			24.5	13.3, 51.6	
Epidemic period	1,094				1,007				5,539			
Pre-pandemic		1.00	Ref	0.800		1.00	Ref	0.800		1.00	Ref	<0.001
Pandemic		0.94	0.56, 1.56			1.10	0.50, 2.62			1.84	1.51, 2.23	
Climatic season	1,094				1,007				5,539			
Dry season		1.00	Ref	0.900		1.00	Ref	0.800		1.00	Ref	0.003
Rainy season		1.06	0.56, 1.88			0.91	0.37, 2.05			1.39	1.12, 1.71	
Geographical region	1,094				1,007				5,539			
North		1.00	Ref	0.007		1.00	Ref	< 0.001		1.00	Ref	0.200
South		2.37	1.31, 4.60			6.51	2.89, 16.0			1.15	0.94, 1.39	
Ecological zone	1,094				1,007				5,539			
Sahel/Sudan Savannah		1.00	Ref	0.002		1.00	Ref	< 0.001		1.00	Ref	<0.001
Derived Savannah		2.77	0.89, 12.1			48.1	9.65, 874			3.78	2.80, 5.16	
Lowland/Freshwater/Mangrove rainforest		6.39	2.27, 26.7			19.1	3.05, 367			2.01	1.45, 2.83	
Guinea Savannah/Jos Plateau		3.34	0.98, 15.3			16.6	2.64, 318			4.35	3.15, 6.07	
Sex	1,092				1,004				5,515			
Female		1.00	Ref	0.800		1.00	Ref	0.065		1.00	Ref	<0.001
Male		1.08	0.65, 1.81			2.40	1.00, 6.68			1.45	1.19, 1.78	
Age group	1,012				1,000				5,309			
0-4 years		1.00	Ref	0.031		1.00	Ref	0.045		1.00	Ref	<0.001
5-9 years		1.15	0.42, 3.27			5.03	0.80, 97.0			2.16	1.33, 3.62	
10-14 years		1.37	0.46, 4.08			1.28	0.05, 32.6			2.60	1.57, 4.41	
15-29 years		2.58	1.13, 6.65			3.88	0.70, 72.2			4.37	2.88, 6.98	
30-44 years		2.88	1.12, 7.93			6.16	1.04, 117			2.96	1.86, 4.89	
45-59 years		0.69	0.04, 4.03			10.4	1.30, 213			3.56	2.07, 6.21	
60+ years		No data				6.78	0.26, 176			1.40	0.58, 3.05	
Educational status	1,094				1,007				5,539			
Educated		1.00	Ref	0.600		1.00	Ref	0.140		1.00	Ref	0.002
No education		0.86	0.51, 1.52			0.55	0.25, 1.24			0.64	0.48, 0.86	
Occupational group	1,094				1,007				5,539			
Home/office worker		1.00	Ref	0.019		1.00	Ref	<0.001		1.00	Ref	< 0.001
Unemployed		2.09	1.13, 3.92			2.13	0.59, 7.75			1.26	1.01, 1.57	

It is made available under a CC-BY 4.0 International license .

Table 5 Cont.												
		Va	ccinated		Unvaccinated				Unknown status			
Characteristic	Total	cOR	95% CI	p-value	Total	cOR	95% CI	p-value	Total	cOR	95% CI	p-value
Student		1.87	0.94, 3.68			3.83	1.14, 13.5			2.40	1.69, 3.35	
Butcher/hunter/farmer		1.38	0.32, 4.21			6.78	2.37, 22.1			3.33	2.15, 5.03	
Artisan/trader		0.50	0.03, 2.48			No data				1.81	0.90, 3.31	
Healthcare worker		7.83	0.38, 64.3			No data				No data		
Occupational setting	526				604				1,084			
Indoor		1.00	Ref	>0.900		1.00	Ref	0.011		1.00	Ref	<0.001
Outdoor		0.98	0.42, 2.15			3.43	1.36, 9.34			2.21	1.55, 3.17	
Traveled within last two weeks	1,094				1,007				5,539			
No		1.00	Ref	0.500		1.00	Ref	0.020		1.00	Ref	<0.001
Yes		2.03	0.11, 11.3			6.21	0.94, 24.1			5.53	3.45, 8.65	
Fatigue	630				647				1,835			
No		1.00	Ref	0.300		1.00	Ref	0.084		1.00	Ref	< 0.001
Yes		0.55	0.16, 1.44			2.24	0.89, 5.73			1.97	1.38, 2.77	
Jaundice	659				677				1,864			
No		1.00	Ref	0.130		1.00	Ref	0.130		1.00	Ref	0.007
Yes		1.89	0.87, 4.54			0.47	0.18, 1.36			1.50	1.12, 2.02	
Hemorrhagic symptoms	618				623				1,751			
No		1.00	Ref	0.06		1.00	Ref	<0.001		1.00	Ref	0.120
Yes		9.75	0.45, 105			23.6	2.96, 151			2.84	0.63, 9.39	
Vomiting	636				649				1,810			
No		1.00	Ref	0.044		1.00	Ref	<0.001		1.00	Ref	<0.001
Yes		2.61	0.94, 6.27			5.18	1.85, 13.6			2.37	1.55, 3.56	
cOR = Crude Odds Ratio												

Table 3 Cont.

CI = Confidence Interval

Vaccinated are cases with previous YF vaccination. Unvaccinated had no previous YF vaccination. Unknown status are cases whose YF vaccination history was not known. Statistically significant p-values are in bold text.

347

349	The predictors of YFD among those with previous YF vaccination were the first quarter of the
350	year compared to the second (aOR: 4.04, 95% CI: 1.48–12.95; p=0.010), residing in the southern
351	region (aOR: 14.03, 95% CI: 4.09-88.27; p<0.001). Clinical symptoms such as jaundice (aOR:
352	2.05, 95% CI: 0.88–5.25; p=0.110) and vomiting (aOR: 2.29, 95% CI: 0.75–6.25; p=0.120) were
353	associated with YFD among the vaccinated but not statistically significant. Predictors among the
354	unvaccinated were male sex (aOR: 6.35, 95% CI: 1.66-32.16; p=0.012), residing in the southern
355	region (aOR: 76.64, 95% CI: 13.57–1465.89; p<0.001), working in outdoor settings (aOR: 3.11, 95%
356	CI: 0.91-12.03; p=0.079), presenting with fatigue (aOR: 3.87, 95% CI: 1.10-15.08; p=0.039),
357	hemorrhagic symptoms (aOR: 368.00, 95% CI: 14.29–14759.72; p<0.001), and vomiting (aOR: 6.53,
358	95% CI: 1.57–27.23; p= 0.009). Predictors of YFD among cases with unknown vaccination status

It is made available under a CC-BY 4.0 International license .

were the third and fourth quarter of the year (aOR: 4.44, 95% CI: 1.92–12.11; aOR: 3.38, 95% CI: 1.08–10.90; p=0.001); age being 15 years or older (aOR: 1.87, 95% CI: 1.17–3.10, p=0.012);and
residing within the Derived Savannah and the Guinea Savannah/Jos Plateau (aOR: 7.09, 95% CI: 3.35–17.45 and aOR: 5.24, 95% CI: 2.41–13.14 respectively; p<0.001) Fig 6.
Fig 6. Seasonal, geographical, socio-demographic, clinical predictors of YFD among reported

cases in Nigeria, 2017-2021 disaggregated by vaccination status.

(A) Unvaccinated (B) Unknown vaccination status. The first column shows the explanatory
 variables, second column show the levels and third column is the adjusted odds ratios with
 corresponding confidence intervals.

_ _ _

It is made available under a CC-BY 4.0 International license .

370 Factors associated with being unvaccinated (barriers to YF 371 vaccination)

Information on vaccination status was available for 3983 out 13014 reported cases, of which 1735 372 373 (13.3%) were vaccinated, 2248 (17.3) were unvaccinated, and 9031 (69.4%) were of unknown status (Table 1). The most unvaccinated age group were those 15-29 years, which also accounted 374 for 30.0% of the total population, 32.0 % of unvaccinated cases, and 27.0% of cases of unknown 375 376 vaccination status (Fig 4 and S1 Table). A comparison of the characteristics of the cases by 377 vaccination status is shown in S1 Table. Independent predictors of being unvaccinated for YF, 378 irrespective of laboratory test status, were the rainy season compared to the dry season (aOR: 1.29, 95% CI: 1.11-1.66, p=0.003); being 15years or older compared to under-five (15-29 years: aOR: 379 2.06, 95% CI: 1.51-2.83; 30-44 years: aOR: 2.11, 95% CI: 1.45-3.07; 45-59 years: aOR: 2.72, 95% 380 381 CI: 1.63-4.58; 60+ years: aOR: 6.55, 95% CI: 2.76-17.50; p<0.001); residing in the northern region compared to the southern region (aOR: 3.71, 95% CI: 3.01-4.58, p<0.001); and occupation 382 being either butcher, farmer or hunter compared to being home-based/officer worker (aOR: 2.30, 383 384 95% CI: 1.52-3.50, p<0.001). Working in outdoor setting was protective against being unvaccinated (aOR: 0.46, 95% CI: 0.31-0.69, p<0.001) (Table 4). 385

- 386
- 387
- 388

- 390
- 391
- 392

It is made available under a CC-BY 4.0 International license .

393	Table 4. Seasonal, geographical, and socio-demographic factors associated with non-vaccination
394	among reported YF cases in Nigeria, 2017-2021.

		Univ	ariate	Multivariable			
Characteristic	Total	Crude OR	95% CI	n-value	Adjusted OR	95% CI	n-value
Enidemic period	3 983		7570 CI	p-value	Rujusicu OK	7570 CI	p-value
Pre-pandemic	3,905	1.00	Ref	0 400			
Pandemic		1.06	0.93. 1.20	0.100			
Climatic season	3.983						
Drv season		1.00	Ref	0.063	1.00	Ref	0.013
Rainv season		1.15	0.99, 1.33		1.29	1.05, 1.57	
Sex	3,971					,	
Female	- ,	1.00	Ref	0.200			
Male		1.09	0.96, 1.24				
Age group	3,862						
0-4 years		1.00	Ref	<0.001	1.00	Ref	<0.001
5-9 years		0.85	0.69, 1.05		0.92	0.66, 1.28	
10-14 years		1.08	0.86, 1.37		1.25	0.86, 1.82	
15-29 years		1.63	1.34, 1.97		2.06	1.51, 2.83	
30-44 years		1.59	1.27, 2.00		2.11	1.45, 3.07	
45-59 year		1.58	1.13, 2.22		2.72	1.63, 4.58	
65+ years		2.28	1.38, 3.89		6.55	2.76, 17.5	
Geographical region	3,983						
South		1.00	Ref	<0.001	1.00	Ref	<0.001
North		4.66	4.07, 5.35		3.71	3.01, 4.58	
Educational status	3,983						
Educated		1.00	Ref	< 0.001	1.00	Ref	0.700
No education		1.39	1.20, 1.59		1.04	0.82, 1.33	
Occupational status	3,983						
Home/office worker		1.00	Ref	<0.001	1.00	Ref	<0.001
Unemployed		1.00	0.85, 1.17		-	-	
Student		0.54	0.45, 0.64		0.62	0.47, 0.83	
Butcher/hunter/farmer		1.91	1.51, 2.42		2.30	1.52, 3.50	
Artisan/trader		0.80	0.58, 1.11		1.45	0.90, 2.37	
Healthcare worker		2.12	0.98, 5.09		1.42	0.63, 3.54	
Occupational setting	2,119						
Indoor		1.00	Ref	0.003	1.00	Ref	<0.001
Outdoor		1.32	1.10, 1.59		0.42	0.28, 0.62	
OR = Odds Ratio							

CI = Confidence Interval

Statistically significant p-values are in bold text.

395

396

To further investigate the effect of the COVID-19 pandemic on YF vaccination, we disaggregated the analysis by laboratory test status. The COVID-19 pandemic period was associated with being unvaccinated among YFV positive (OR: 2.43, 95% CI: 0.96-6.48, p=0.066) and negative cases

It is made available under a CC-BY 4.0 International license .

- 400 (OR: 2.06, 95% CI: 1.73-2.47, p<0.001) compared to the pre-pandemic period, just as working in
- 401 outdoor settings in comparison to working indoors (OR: 3.81, 95% CI: 1.16-13.6, p=0.032) among
- 402 YFV positive cases (Table 5).

403 Table 5. Factors associated with non-vaccination among reported Yellow fever cases in 403 Nine 2015 2021 Nine 2015 Nine 2015

404 Nigeria, 2017-2021 disaggregated by laboratory test status.

	Positive cases				Negative cases				Unconfirmed cases			
Characteristic	Ν	cOR	95% CI	p-value	Ν	cOR	95% CI ¹	p-value	Ν	cOR	95% CI	p-value
Epidemic period	90				2,011				442			
Pre-pandemic		1.00	Ref	0.066		1.00	Ref	<0.001		1.00	Ref	0.120
Pandemic		2.43	0.96, 6.48			2.06	1.73, 2.47			0.34	0.22, 0.54	
Climatic season	90				2,011				442			
Dry season		1.00	Ref			1.00	Ref			1.00	Ref	0.060
Rainy season		1.45	0.51, 3.96	0.500		1.69	1.39, 2.06	<0.001		0.59	0.34, 1.03	
Geographical region	90				2,011				442			
South		1.00	Ref	0.300		1.00	Ref	<0.001		1.00	Ref	<0.001
North		1.74	0.60, 4.86			4.79	3.96, 5.80			6.71	4.23, 10.8	
Sex	88				2,008				439			
Female		1.00	Ref	0.110		1.00	Ref	0.600		1.00	Ref	0.100
Male		2.33	0.85, 7.14			1.05	0.88, 1.25			1.43	0.93, 2.19	
Age group	83				1,929				1,850			
0-4 years		1.00	Ref	0.053		1.00	Ref	< 0.001		1.00	Ref	< 0.001
5-9 years		3.89	0.47, 83.8			0.89	0.66, 1.19			0.82	0.60, 1.11	
10-14 years		1.00	0.03, 28.8			1.07	0.78, 1.48			1.21	0.85, 1.73	
15-29 years		2.55	0.36, 51.5			1.70	1.30, 2.22			1.67	1.26, 2.22	
30-44 years		3.50	0.46, 73.3			1.64	1.19, 2.26			1.67	1.18, 2.36	
45-59 years		21.0	1.33, 913			1.39	0.87, 2.25			1.68	1.03, 2.81	
60+ years			No data			2.03	1.02, 4.17			2.48	1.16, 5.95	
Educational status	90				2,011				1,882			
Educated		1.00	Ref	0.300		1.00	Ref	0.800		1.00	Ref	< 0.001
No education		0.62	0.24, 1.61			0.98	0.80, 1.19			2.10	1.70, 2.60	
Occupational group	90				2,011				442			
Home-based/Office worker		1.00	Ref	0.002		1.00	Ref	< 0.001		1.00	Ref	< 0.001
Unemployed		0.87	0.21, 3.55			0.85	0.68, 1.07			2.02	1.11, 3.83	
Student		1.50	0.38, 6.09			0.73	0.57, 0.94			0.21	0.11, 0.41	
Butcher/farmer/hunter		13.3	2.92, 79.5			2.72	1.93, 3.88			0.86	0.45, 1.73	
Artisan/Trader		Miss				0.90	0.58, 1.40			0.38	0.11, 1.37	
		ing										
Healthcare worker		Miss				6.70	2.27, 28.7			0.32	0.01, 8.10	
		ing										
Occupational setting	48				1,082				225			
Indoor		1.00	Ref	0.032		1.00	Ref	0.500		1.00	Ref	0.150
Outdoor		3.81	1.16, 13.6			1.09	0.85, 1.41			1.52	0.87, 2.70	

cOR = Crude Odds Ratio

CI = Confidence Interval

Positive cases are YFV laboratory confirmed cases of YF.

Negative cases are suspected cases that tested negative for YFV. Unconfirmed cases are suspected cases that had no laboratory confirmation.

Statistically significant p-values are in bold text.

405

It is made available under a CC-BY 4.0 International license .

407	More independent predictors were seen among YFV negative cases, which include the COVID-
408	19 pandemic period (aOR: 1.40, 95% CI: 1.14-1.72, p=0.002), age group being 15-29, 30-44, 60+
409	years (aOR: 1.81, 95% CI: 1.28-2.57; aOR: 1.79, 95% CI: 1.19-2.69; and aOR: 2.25, 95% CI:
410	1.03-5.02; p=0.001), residing in the northern region (aOR: 4.39, 95% CI: 3.58-5.40, p<0.001); and
411	occupation being butcher/farmer/hunter, and health worker (aOR: 1.63, 95% CI: 1.08-2.47; aOR:
412	4.03, 95% CI: 1.33-17.47; p=0.021) (Fig 7).
413	
414	Fig 7. Seasonal, geographical, and socio-demographic predictors non-vaccination among
415	reported cases in Nigeria, 2017-2021 disaggregated by laboratory test status.
416	(A) Negative (B) Unconfirmed cases. The first column shows the explanatory variables, second
417	column show the levels and third column is the adjusted odds ratios with corresponding confidence
418	intervals.
419	
420	Among YFV positive cases, independent predictors of being unvaccinated were COVID-19
421	pandemic period (aOR: 3.08, 95% CI: 0.86-12.55, p=0.09) and working in outdoor settings (aOR:
422	3.89, 95% CI: 1.13-14.64, p=0.03).
423	
424	

It is made available under a CC-BY 4.0 International license .

428 **Discussion**

429 Recommended control strategies for YF under the WHO EYE strategy include effective and timely surveillance, strengthening laboratory services, adequate routine immunization coverage and a 430 comprehensive response to outbreaks of YF [11,17,29,30]. In Nigeria, YF surveillance is a passive, 431 health facility-based, case-based, laboratory-based, surveillance system [18]. Most suspected cases 432 reported during the study period were not confirmed by laboratory test, which may be because 433 434 cases did not present early enough at health facilities to enable prompt detection of YFV by RT-PCR within the ten-day window period for detection of the viral genome in blood samples. 435 Logistical challenges associated with sample transportation from Nigeria to the Regional 436 Reference Laboratory in Dakar, Senegal for confirmation of presumptive positive and inconclusive 437 RT-PCR negative samples by PRNT may be another possible reason [18]. Late presentation of 438 439 cases at health facility may have also contributed to the large proportion of suspected cases that tested negative for YFV despite meeting the case definition. These challenges may be surmounted 440 by investment in community-based surveillance to enable prompt case detection and building in-441 country capacity for full complement of serological testing. In Côte d'Ivoire, an eight-fold increase 442 in suspected YF case reporting was documented following implementation of community-based 443 surveillance [31]. 444

The odds of YFD increased significantly from the 2017 epidemic season through the 2020 season, which was followed by an abrupt decrease in the 2021 season. The 2020 epidemic season coincided with the commencement of the COVID-19 pandemic. Thus, the decrease in case reporting observed during the pandemic period may be a pointer to the disruptive effect of the COVID-19 pandemic on YF surveillance activities in Nigeria [32]. The pandemic resulted in the conversion of several public hospitals to COVID-19 treatment centers in Nigeria and elicited patients' apathy

towards hospital attendance [33]. We have shown that cases were about twice as likely to be unvaccinated for YF during the pandemic period. Ayobami et al (2023) had reported that the COVID-19 pandemic was associated with reduction in care seeking for children and clinic attendance for childhood immunization [33]. Similarly, Ribeiro da Silva et al (2022) reported a reduction in the number of YF vaccine doses administered in Brazil during the pandemic period compared to the pre-pandemic era [34].

Our study has shown that YF outbreaks in Nigeria followed a distinct seasonal pattern in which 457 case incidence followed the rainy season progression. Previous studies in Uganda and Brazil have 458 reported a rainy season driven YF outbreak pattern [35,36]. The YF mass vaccination campaigns 459 implemented in Nigeria between 2017 and 2019 were carried out in September of each year [5]. 460 461 We showed that cases were nearly twice more likely to be unvaccinated during the rainy season. The rainy season is the farming season in Nigeria, and farmers tend to spend most of their daytime 462 in their farms during this time of year. Perhaps, commencing reactive vaccination early in the year 463 464 (January - April) may increase the chances of getting more persons vaccinated, especially in areas where people are predominantly farmers or get involved in other forest-going occupation. 465

The most-at-risk population in this study were younger people, especially males. A similar study 466 in Brazil reported males with a median age of 26 (range: 1-93) years, with the most affected age 467 group being 20-29 years [23]. Ribeiro et al. also found males with a mean age of 29 years [37]. We 468 469 found that cases in the age group 15-29 years had over two-fold odds of being unvaccinated and over four-fold odds of having YFD. Higher odds of YFD in males compared to females seen in 470 this study has been attributed to occupation. A study in Uganda found that cases were 471 predominantly males involved in rural agricultural activities in forested, swampy areas - an 472 observation that has also been reported in Ethiopia [4,35]. 473

The finding that cases without any travel history featured prominently in the epidemic suggests 474 the presence of suitable conditions for YFV transmission locally [6]. However, persons with travel 475 history had over five-fold odds of YFD compared to those that did not. Studies in Uganda [35] and 476 Brazil [23] have incriminated traveling to YF endemic areas as risk factor for infection. This 477 observation may not be unconnected with ecological characteristics. We found that the north-west 478 479 geo-political zone, which straddles parts of the Guinea Savannah, Jos Plateau, Sahel Savannah, and the Sudan Savannah, reported the highest proportion of suspected cases but YFV positivity 480 was highest in the south-east, which occupies parts of the Derived Savannah and the Lowland 481 482 rainforest. Nomhwange et al (2021) had previously identified four epidemiological blocks of YFV spread in Nigeria, delineated by the geo-political zones: block 1 around the north-central; block 2 483 in the south-south; block 3 in the south-east; and block 4 in the north-east [5]. The outbreak in the 484 north-central block has been reported to spread into the north-west while the south-south block 485 spreads into the south-west. Our findings, however, suggest that YFV transmission in these 486 epidemiological blocks seemed to be related to the characteristics of the ecological zones that 487 occupy the geo-political zones. We demonstrated for the first time, to our knowledge, the important 488 contribution of the Derived Savannah, the Lowland/Freshwater/Mangrove rainforest, and the 489 Guinea Savannah/Jos Plateau to YF epidemiology in Nigeria. Of concern is the double jeopardy 490 491 of the higher odds YFD among unvaccinated and vaccinated persons in the Lowland/Freshwater/Mangrove rainforest ecological zone, which mainly occupy the south-south 492 493 and south-west geo-political zones. We further showed that the odds of YFD in the Derived Savannah and the Guinea Savannah/Jos Plateau could be mitigated by adequate vaccination as 494 these ecological zones largely lie in the northern region where cases had about five-fold odds of 495 496 being unvaccinated compared to those in the southern region. A combination of human, reservoir,

It is made available under a CC-BY 4.0 International license .

497 and vector surveillance studies, in addition to the effects of human encroachment may provide 498 further insight as to whether the varying degree of risk of YFD seen across the ecological zones in 499 this study is driven by specific characteristics. In Brazil, where the YFV has demonstrated its 500 ability to expand its geographic spread since 2016, human activities have been implicated as 501 contributing factor [36,38].

Clinically, the viraemia phase of YF is characterized by fever, headache, chills, backache, fatigue, 502 anorexia, nausea, and vomiting, whereas the toxaemic phase is marked by high fever, worsening 503 headache, chills, muscle pain and signs of multiple organs and systems involvement. Hepatic 504 505 coagulopathy leads to severe hemorrhagic manifestations [6]. These symptoms were manifested by the cases reported in this study, just as had also been reported in Uganda [35] and Brazil [2,39]. 506 YF is distinguished from other hemorrhagic fevers caused by viruses by the characteristic liver 507 damage and presentation of jaundice [6]. Presenting fatigue, hemorrhagic symptoms and vomiting 508 were significantly associated with YFD among the unvaccinated in our study. These factors may 509 510 be important in strengthening YF case definition for the purpose of surveillance as well enhancing index of suspicion by clinicians and surveillance officers. 511

512 Vaccination is widely recognized as the most potent weapon to combat YF outbreaks. Following 513 the resurgence of YF outbreak in 2017 in Nigeria, efforts were made to revamp up YF vaccination coverage. A total 45,648,243 persons of age less than 45 years were vaccinated across Nigeria 514 515 through nine targeted reactive mass vaccination campaigns and three phased mass vaccination 516 activities. [5]. The coverage achieved by these campaigns has not proved to adequately protect the 517 population against YFV spread. In developing a strategy to enhance vaccine uptake in Nigeria, it is imperative that policy makers take into cognizance the potential barriers to YF vaccination. The 518 519 independent predictors of being unvaccinated were the COVID-19 pandemic period, rainy season,

being 15 years or older, residing in northern Nigeria, being a butcher, farmer, or hunter and being 520 a healthcare worker. To meet the 2026 target of the WHO EYE strategy, a review of the current 521 policy on vaccination may be warranted to achieve sufficient coverage that could halt YFV 522 transmission in Nigeria. A sizeable proportion of vaccinated cases were found to be positive for 523 YFV and hospitalized, pointing to evidence of possible vaccine failure. A similar finding was 524 525 reported by Tuboi et al (2007) in Brazil [23]. It may be difficult to pinpoint the reason for this. It is, however, known that the 17D YF vaccine is a live attenuated vaccine, and it is possible that its 526 527 efficacy may be affected by factors related to proper handling, transport, storage, and usage, which could be challenging in resource-poor settings [23,40]. The involvement of vaccinated cases in the 528 epidemic coincided with the period of implementation of reactive YF vaccination campaigns in 529 Nigeria. The highest incidence was seen during the 2019 epidemic season, largely among cases 530 531 15-29 year, working in indoor setting and residing largely in the Derived Savannah, Lowland rainforest, and the Sudan Savannah. This brings to the fore the crucial need for invest investments 532 533 research tools that would enable understanding of the molecular epidemiology of the YFV in Nigeria. 534

535 Limitation

This study represents the first attempt in Nigeria to use multi-season national surveillance data to characterize the seasonal, geographical, socio-demographic, and clinical characteristics associated with YFD and to identify barriers to vaccination. The dataset was generated from different health facilities across Nigeria, making it quite representative. However, just like every other surveillance system, the national YF surveillance in Nigeria is not without limitations. First, it is a passive, health facility-based surveillance system, which relies on the judgement of clinicians to identify cases. Although, under outbreak conditions, an active and community-based component of the

surveillance system is activated. Considering the broad range of clinical presentation and 543 symptoms associated with YF and the passive nature of the surveillance system, less severe cases 544 may have been missed. However, clinicians and focal persons were trained regularly on using a 545 WHO standard case definition to identify YF cases. Second, the national line list does not capture 546 information on co-morbidities and pre-existing illnesses such as liver disease or previous toxic 547 548 exposures such as alcohol consumption that may be confounding factors in YF disease. Third, there were issues related to data quality, including missing data, however, the development and 549 deployment of the SORMAS platform, has strengthened the surveillance of diseases captured 550 551 under the IDSR system, including YF in Nigeria, providing real time data entry and analysis. In any case, secondary data is useful for planning preventive measures, healthcare assessment, and 552 research[41]. Findings from our study has the potential to be generalized as the dataset used had 553 554 national representation, covering the six geo-political zones in Nigeria. However, it is important to note that the dataset used for the study was largely hospital-based. This implies that cases who 555 felt they were not ill enough to access care in a health facility setting were completely missed by 556 this study. 557

558 **Conclusion**

559 In conclusion, following its resurgence in 2017, YF outbreaks in Nigeria occurred annually with increasing odds of incidence until the 2020 epidemic season. Despite the epidemic following the rainy 560 561 season pattern with the peak incidence seen between September and November annually, the odd of YFD was higher during the dry season. A combination of factors has proven to be important drivers of YF 562 outbreaks in Nigeria. Although vaccination has proven to reduce the odds of YFD, the higher odds of 563 564 YFD among previously vaccinated persons, especially those residing in the southern region suggests that 565 inadequate vaccination alone may not explain the recurrent YF incidence in Nigeria, warranting further research using genomic surveillance tools. To improve YF vaccine uptake, current policy on vaccination 566

It is made available under a CC-BY 4.0 International license .

567 campaigns and routine immunization may need to be reviewed to address the barriers to YF vaccination 568 identified in this study. The COVID-19 pandemic, the rainy season, being 15 years or older, residing in 569 the northern region, and certain occupation have been shown to be impediment to YF vaccination. Our 570 findings are critical for planning public health interventions and to guide research strategies that would 571 enable Nigeria to meet the 2026 target of the WHO EYE strategy.

572

573 Supporting information

574 S1 Fig: Map of Nigeria. (a) geo-political zones (b) ecological

575 Zones

576 S1 Table. Comparison of seasonal, geographical, and socio-

577 demographic characteristics among reported Yellow fever

cases in Nigeria, 2017-2021 by vaccination status.

579 Acknowledgement

We sincerely appreciate the Program for Nurturing Global Leaders in Tropical and Emerging
Communicable Diseases, Graduate School of Biomedical Sciences, Nagasaki University, the
Management of the Nigeria Centre for Disease Control, and Japan International Cooperation
Agency.

584 Author contributions

585 **Conceptualization:** Stephen E. Akar, Kaneko Satoshi

It is made available under a CC-BY 4.0 International license .

- **Data curation:** Stephen E. Akar, Akanimo Iniobong, William Nwachukwu, Chinwe Ochu,
- 587 Olajumoke Babatunde, Ifedayo Adetifa, Chikwe Ihekweazu
- 588 **Data analysis:** Stephen E. Akar, Kaneko Satoshi
- 589 Methodology: Stephen E. Akar, Mami Hitachi, Kentaro Kato, Kaneko Satoshi
- 590 **Supervision:** Satoshi Kaneko, Yuki Takamatsu, Kenji Hirayama
- 591 Validation: Satoshi Kaneko, Kentaro Kato, Mami Hitachi, Stephen E. Akar
- 592 Writing original (original draft): Stephen E. Akar, Satoshi Kaneko
- 593 Writing (review and editing): Stephen E. Akar, William Nwachukwu, Akanimo Iniobong,
- 594 Oyeladun Okunromade, Chinwe Ochu, Olajumoke Babatunde, Ifedayo Adetifa, Chikwe
- 595 Ihekweazu, Mami Hitachi, Kentaro Kato, Yuki Takamatsu, Kenji Hirayama, Satoshi Kaneko

596 Funding

- 597 SEA received funding in the form of PhD fellowship scholarship from the Japan International
- 598 Cooperation Agency (https://www.jica.go.jp/english/) for implementation of this research work.
- 599 The funders had no role in study design, data collection and analysis, decision to publish, or 600 preparation of the manuscript.

Data Availability Statement

The dataset used in our study is a third-party data archived with the NCDC, which is the national public health institute in Nigeria. Access is granted by the NCDC on request for specific dataset. Such request could be directed to dgo@ncdc.gov.ng.

605 **References**

606	1.	Tomori O. Impact of yellow fever on the developing world. Adv Virus Res. 1999;53: 5–34.
607		doi:10.1016/s0065-3527(08)60341-3

- Escosteguy CC, Pereira A, Marques M, de Araujo Lima T, Galliez R, de Andrade MR. Yellow fever:
 Profile of cases and factors associated with death in a hospital in the State of Rio de Janeiro,
 2017-2018. Rev Saude Publica. 2019;53: 89. doi:10.11606/S1518-8787.2019053001434
- 8. Rugarabamu S, Mwanyika GO, Rumisha SF, Sindato C, Lim HY, Misinzo G, et al. Seroprevalence
 and associated risk factors of selected zoonotic viral hemorrhagic fevers in Tanzania. Int J Infect
 Dis. 2021;109: 174–181. doi:10.1016/J.IJID.2021.07.006
- Asebe G, Michlmayr D, Mamo G, Abegaz WE, Endale A, Medhin G, et al. Seroprevalence of Yellow
 fever, Chikungunya, and Zika virus at a community level in the Gambella Region, South West
 Ethiopia. PLoS One. 2021;16: e0253953. doi:10.1371/JOURNAL.PONE.0253953
- 5. Nomhwange T, Jean Baptiste AE, Ezebilo O, Oteri J, Olajide L, Emelife K, et al. The resurgence of
 yellow fever outbreaks in Nigeria: a 2-year review 2017–2019. BMC Infect Dis. 2021;21: 1–12.
 doi:10.1186/S12879-021-06727-Y/TABLES/2
- 6. Adogo LY, Ogoh MO. Yellow fever in Nigeria: A review of the current situation. Afr J Clin Exper
 Microbiol. 2019;21: 1–13. doi:10.4314/ajcem.v21i1.1
- Tsegaye MM, Beyene B, Ayele W, Abebe A, Tareke I, Sall A, et al. Sero-prevalence of yellow fever
 and related Flavi viruses in Ethiopia: A public health perspective. BMC Public Health. 2018;18:
 1011. doi:10.1186/s12889-018-5726-9
- Abdullahi IN, Anka AU, Emeribe AU, Umar K, Adekola HA, Uzairue L, et al. The interplay between
 environmental factors, vector competence and vaccine immunodynamics as possible explanation
 of the 2019 yellow fever re-emergence in Nigeria. New Microbes and New Infect. 2021;41:
 100858. doi:10.1016/j.nmni.2021.100858
- Monath TP. Review of the risks and benefits of yellow fever vaccination including some new
 analyses. Expert Rev Vaccines. 2012;11: 427–448. doi:10.1586/ERV.12.6
- 631 10. Verma R, Khanna P, Chawla S. Yellow fever vaccine: An effective vaccine for travelers. Hum
 632 Vaccin Immunother. 2014;10: 126–128. doi:10.4161/HV.26549
- 11. Nwachukwu WE, Yusuff H, Nwangwu U, Okon A, Ogunniyi A, Imuetinyan-Clement J, et al. The
 response to re-emergence of yellow fever in Nigeria, 2017. Int J Infect Dis. 2020;92: 189–196.
 doi:10.1016/j.ijid.2019.12.034
- Collins ND, Barrett ADT. Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still
 Controlling Outbreaks In Modern Day. Curr Infect Dis Rep . 2017;19: 14. doi:10.1007/S11908-017 0566-9
- Bonaldo MC, Sequeira PC, Galler R. The yellow fever 17D virus as a platform for new live
 attenuated vaccines. Hum Vaccin Immunother. 2014;10: 1256–1265. doi:10.4161/HV.28117

It is made available under a CC-BY 4.0 International license .

641 642 643	14.	Servadio JL, Muñoz-Zanzi C, Convertino M. Estimating case fatality risk of severe Yellow Fever cases: systematic literature review and meta-analysis. BMC Infect Dis. 2021;21: 819. doi:10.1186/s12879-021-06535-4
644 645 646	15.	Wariri O, Edem B, Nkereuwem E, Nkereuwem OO, Umeh G, Clark E, et al. Tracking coverage, dropout and multidimensional equity gaps in immunisation systems in West Africa, 2000–2017. BMJ Glob Health. 2019;4: e001713. doi:10.1136/bmjgh-2019-001713
647 648 649	16.	Blanco MZ, Ola JK, Faiyaz A, De Guzman A, De VC, Reyes L, et al. Risk of Yellow fever outbreak in a rural community: Assessment of knowledge, attitude and prevalence of risk factors in Nigeria. International Journal of Infectious Diseases. 2020;101: 265–272. doi:10.1016/j.ijid.2020.09.705
650 651 652	17.	WHO. Eliminate yellow fever epidemics (EYE) strategy 2017-2026. [cited 5 Jul 2023]. Available: https://www.who.int/initiatives/eye- strategy#:~:text=The%20EYE%20strategy%20is%20a,contain%20outbreaks%20rapidly.
653 654 655	18.	Nigerian Centre for Disease. National Guidelines for Yellow Fever Preparedness and Response. Abuja; 2019. Report No.: 1. Available: https://www.ncdc.gov.ng/themes/common/docs/protocols/118_1581155661.pdf
656 657	19.	Olajuyigbe S. Green gold of Africa: Nigeria's forest, a depleted but resilient renewable resource. Irish Forestry. 2018;75: 92–111.
658 659 660	20.	Federal Ministry of Environment. National Forest Reference Emission Level (FREL). Final report. Abuja. Department of Forestry, FMoE, Federal Republic of Nigeria; 2019 Jan. Report No.: 1. Available: https://redd.unfccc.int/files/nigeria_national_frel_modified_revisedfor_posting.pdf
661 662 663 664	21.	Olaleye OA, Ameh CE (Department of Forestry). Data Collection and Analysis for Sustainable Forest Management in ACP Countries - Linking National and International Efforts (Forest Resource Situation Assessment of Nigeria). Final report. Abuja: EC-FAO Partnership Programme (1998-2002); 1999 Apr. Available: https://www.fao.org/3/ab578e/ab578e.pdf
665 666 667	22.	Mengesha Tsegaye M, Beyene B, Ayele W, Abebe A, Tareke I, Sall A, et al. Sero-prevalence of yellow fever and related Flavi viruses in Ethiopia: a public health perspective. BMC Public Health. 2018;18: 1011. doi:10.1186/s12889-018-5726-9
668 669 670	23.	Tuboi SH, Costa ZGA, da Costa Vasconcelos PF, Hatch D. Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998-2002. Trans R Soc Trop Med Hyg. 2007;101: 169–175. doi:10.1016/j.trstmh.2006.04.001
671 672	24.	Venables WN, Riply BD. Modern Applied Statistics with S. 4th ed. Oxford: Springer; 2002. Available: https://www.stats.ox.ac.uk/pub/MASS4/
673 674	25.	Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, et al. Welcome to the Tidyverse. J Open Source Softw. 2019;4: 1686. doi:10.21105/joss.01686
675 676	26.	Kazuki Yoshida. Introduction to tableone. [cited 20 May 2023]. Available: https://cran.r- project.org/web/packages/tableone/vignettes/introduction.html

It is made available under a CC-BY 4.0 International license .

677 678	27.	Sjoberg DD, Whiting K, Curry M, Lavery JA, Larmarange J. Reproducible Summary Tables with the gtsummary Package. R J. 2021;13: 570–580.
679 680	28.	Rami Krispin. Applied Time Series Analysis and Forecasting with R. 1st ed. Online: Github; 2021. Available: https://ramikrispin.github.io/atsaf/
681 682	29.	Chen LH, Wilson ME. Yellow fever control: current epidemiology and vaccination strategies. Trop Dis Travel Med Vaccines. 2020;6: 1–10. doi:10.1186/s40794-020-0101-0
683 684	30.	Hansen CA, Barrett ADT. The present and future of yellow fever vaccines. Pharmaceuticals. 2021;14: 891. doi:10.3390/ph14090891
685 686	31.	Clara A, Ndiaye SM, Joseph B, Nzogu MA, Coulibaly D, Alroy KA, et al. Community-Based Surveillance in Côte d'Ivoire. Health Secur. 2020;18: S23–S33. doi:10.1089/hs.2019.0062
687 688	32.	Shioda K, Weinberger DM, Mori M. Navigating through Health Care Data Disrupted by the COVID- 19 Pandemic. JAMA Intern Med. 2020;180: 1569–1570. doi:10.1001/jamainternmed.2020.5542
689 690 691 692	33.	Bakare AA, Olojede OE, King C, Graham H, Uchendu O, Colbourn T, et al. Care seeking for under- five children and vaccine perceptions during the first two waves of the COVID-19 pandemic in Lagos State, Nigeria: a qualitative exploratory study. BMJ Open. 2023;13: e069294. doi:10.1136/BMJOPEN-2022-069294
693 694 695	34.	Silva TMR, Nogueira de Sá ACMG, Prates EJS, Rodrigues DE, Silva TPR, Matozinhos FP, et al. Yellow fever vaccination before and during the covid-19 pandemic in Brazil. Rev Saude Publica. 2022;56: 45. doi:10.11606/s1518-8787.2022056004503
696 697 698	35.	Kwagonza L, Masiira B, Kyobe-Bosa H, Kadobera D, Atuheire EB, Lubwama B, et al. Outbreak of yellow fever in central and southwestern Uganda, February-may 2016. BMC Infect Dis. 2018;18: 548. doi:10.1186/S12879-018-3440-Y
699 700 701 702	36.	Abreu FVS de, de Andreazzi CS, Neves MSAS, Meneguete PS, Ribeiro MS, Dias CMG, et al. Ecological and environmental factors affecting transmission of sylvatic yellow fever in the 2017– 2019 outbreak in the Atlantic Forest, Brazil. Parasit Vectors. 2022;15: 23. doi:10.1186/s13071- 021-05143-0
703 704 705 706	37.	Ribeiro AF, Cavalin RF, Suleiman JMAH, Da Costa JA, De Vasconcelos MJ, Málaque CMSA, et al. Yellow fever: Factors associated with death in a hospital of reference in infectious diseases, São Paulo, Brazil, 2018. American Journal of Tropical Medicine and Hygiene. 2019;101: 180–188. doi:10.4269/ajtmh.18-0882
707 708 709	38.	Faria NR, Kraemer MUG, Hill SC, De Jesus JG, Aguiar RS, Iani FCM, et al. Genomic and epidemiological monitoring of yellow fever virus transmission potential. Science (1979). 2018;361: 894–899. doi:10.1126/SCIENCE.AAT7115
710 711 712	39.	Kallas EG, D'Elia Zanella LGFAB, Moreira CH V., Buccheri R, Diniz GBF, Castiñeiras ACP, et al. Predictors of mortality in patients with yellow fever: an observational cohort study. Lancet Infect Dis. 2019;19: 750–758. doi:10.1016/S1473-3099(19)30125-2

It is made available under a CC-BY 4.0 International license .

- 71340.Stefano I, Sato HK, Pannuti CS, Omoto TM, Mann G, Freire MS, et al. Recent immunization against714measles does not interfere with the sero-response to yellow fever vaccine. Vaccine. 1999;17:
- 715 1042–1046. doi:10.1016/S0264-410X(98)00320-X
- 716 41. Sorensen T, Sabroe S, Olsen J. A Framework for Evaluation of Secondary Data Sources for
- 717 Epidemiological Research. Int J Epidemiol. 1996;25: 435–442. Available:
- 718 https://academic.oup.com/ije/article/25/2/435/688378

It is made available under a CC-BY 4.0 International license .







(D) Unknown status





(A) Negative cases

Epidemic.period	Before pandemic	-	
	During pandemic	1.40 (1.14-1.72, p=0.002)	
Age.group	0-4	_	
- 3 - 3 - - -	5-9	0.89 (0.65-1.23, p=0.488)	
	10-14	1.13 (0.79-1.61, p=0.515)	
	15-29	1.81 (1.28-2.57, p=0.001)	
medRxiv preprint doi: http preprint (which was not cer	os://doi.org/10.1101/2023.09.20.23295 r tified by peer review) is the auth or/fu	820; this version posted September 22, 2023. The copyright holder for this inder, who has granted med xiv a license to display the preprint in perpetuity.	
	It is made available unde	r a CC-BY 4.01ht66tip00195s2.92, p=0.076)	
	60+	2.25 (1.03-5.02, p=0.044)	+ -
Geographical.rec	ion South	(, p,	
	North	4.39 (3.58-5.40, p<0.001)	
Occupation	Home-based/office		
	Unemployed	0.95 (0.68-1.33, p=0.767)	
	Student	0.83 (0.62-1.10, p=0.200)	
Bu	tcher/farmer/hunter	1.63 (1.08-2.47, p=0.021)	
Artisan/trader		0.92 (0.55-1.53, p=0.736)	
	Health worker	4 03 (1 33-17 47 p=0.028)	
	ricular worker	4.00 (1.00 11.11, p=0.020)	
		-	
			1 5 10 20

(B) Unconfirmed cases

Climatic.season	Dry season	
	Rainy season	1.28 (0.94-1.75, p=0.115)
Age.group	0-4	
0 0 1	5-9	1.01 (0.62-1.63, p=0.969)
	10-14	2.01 (1.15-3.54, p=0.015)
	15-29	2.85 (1.81-4.52, p<0.001)
	30-44	2.56 (1.49-4.44, p=0.001)
	54-59	4.17 (2.01-9.06, p<0.001)
	60+	10.76 (2.58-74.36, p=0.004)
Geographical.region	South	
	North	3.05 (2.24-4.18, p<0.001)
Educational.status	Education	
	No education	1.31 (0.92-1.86, p=0.136)
Occupation Hom	ne-based/office	
	Unemployed	
	Student	0.58 (0.38-0.88, p=0.010)
Butche	r/farmer/hunter	1.28 (0.67-2.40, p=0.449)
	Artisan/trader	1.10 (0.52-2.32, p=0.799)
	Health worker	0.40 (0.09-1.81, p=0.218)
Occupational.setting	Indoor	
	Outdoor	0.66 (0.35-1.26, p=0.207)



OR, 95% CI





(A) Unvaccinated cases



(B) Unknown vaccination status

Annual.quart	er Secon	d quarter		-
	Firs	st quarter	0.98 (0.28-3.4	5, p=0.972)
	Thir	d quarter	4.44 (1.92-12.1	1, p=0.001)
	Fourt	h quarter	3.38 (1.08-10.9)	0, p=0.035)
Climatic.sea	son Dr	y season		-
	Rain	y season	0.21 (0.08-0.44	4, p<0.001)
Age.group	<	15 years		-
	>=	15 years	1.87 (1.17-3.1)	0, p=0.012)
Eco.zone	Sahel/Sudan s	savannah		-
	Derived s	savannah	7.09 (3.35-17.4	5, p<0.001)
Lowland/Freshwater rainforest			1.26 (0.53-3.3	6, p=0.614)
Guinea savannah/Jos Plateau			5.24 (2.41-13.14	4, p<0.001)
Fatigue		No		-
		Yes	1.25 (0.78-1.9	6, p=0.338)
Vomiting		No		-
		Yes	1.35 (0.75-2.3)	7, p=0.301)
Hemorrhagio	symptoms.	No		-
		Yes	2.94 (0.59-11.8	1, p=0.147)



